To REMS, or not to REMS. That apparently was the question for Cytokinetics, which has seen any potential approval for its ...

The National Institutes of Health is making a major change to how grant recipients can use their funds. | The National ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

The U.S. government is putting down $500 million toward the development of a “universal” vaccine—a shot designed to protect ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve ...

The National Institutes of Health (NIH) is planning to freeze the flow of funds to institutions outside of the U.S., ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences. | With the walls quickly closing in, Kronos Bio has accepted a buyout from ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...